Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternate splicing of this gene results in two transcript variants encoding two different isoforms which are differentially expressed.[9]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Yoshida S, Taniguchi M, Suemoto T, Oka T, He X, Shiosaka S (Oct 1998). "cDNA cloning and expression of a novel serine protease, TLSP". Biochim Biophys Acta. 1399 (2–3): 225–8. doi:10.1016/s0167-4781(98)00116-x. PMID9765601.
^Yousef GM, Scorilas A, Diamandis EP (Apr 2000). "Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family". Genomics. 63 (1): 88–96. doi:10.1006/geno.1999.6072. PMID10662548.
^Diamandis EP, Deperthes D, Lundwall Å (Jun 2006). "Proceedings of the 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3, 2005". Biol Chem. 387 (6): 635–824. doi:10.1515/BC.2006.081. PMID16800723. S2CID83910246.
Mitsui S, Yamada T, Okui A, et al. (2000). "A novel isoform of a kallikrein-like protease, TLSP/hippostasin, (PRSS20), is expressed in the human brain and prostate". Biochem. Biophys. Res. Commun. 272 (1): 205–11. doi:10.1006/bbrc.2000.2761. PMID10872828.
Gan L, Lee I, Smith R, et al. (2001). "Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region". Gene. 257 (1): 119–30. doi:10.1016/S0378-1119(00)00382-6. PMID11054574.
Nakamura T, Mitsui S, Okui A, et al. (2002). "Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines". Prostate. 49 (1): 72–8. doi:10.1002/pros.1119. PMID11550212. S2CID21572408.
Diamandis EP, Okui A, Mitsui S, et al. (2002). "Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma". Cancer Res. 62 (1): 295–300. PMID11782391.
Nakamura T, Mitsui S, Okui A, et al. (2003). "Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate". Prostate. 54 (4): 299–305. doi:10.1002/pros.10191. PMID12539228. S2CID21482369.
Nakamura T, Stephan C, Scorilas A, et al. (2003). "Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues". Urology. 61 (5): 1042–6. doi:10.1016/S0090-4295(02)02443-3. PMID12736044.
Shigemasa K, Gu L, Tanimoto H, et al. (2004). "Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer". Clin. Cancer Res. 10 (8): 2766–70. doi:10.1158/1078-0432.CCR-03-0269. PMID15102682. S2CID1192794.
Diamandis EP, Borgoño CA, Scorilas A, et al. (2005). "Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients". Clin. Biochem. 37 (9): 823–9. doi:10.1016/j.clinbiochem.2004.04.009. PMID15329323.
Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A (2005). "Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer". Clin. Chim. Acta. 357 (2): 190–5. doi:10.1016/j.cccn.2005.03.026. PMID15893744.
Planque C, Aïnciburu M, Heuzé-Vourc'h N, et al. (2006). "Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues". Biol. Chem. 387 (6): 783–8. doi:10.1515/BC.2006.098. PMID16800740. S2CID6937753.
Mitsui S, Nakamura T, Okui A, et al. (2006). "Multiple promoters regulate tissue-specific alternative splicing of the human kallikrein gene, KLK11/hippostasin". FEBS J. 273 (16): 3678–86. doi:10.1111/j.1742-4658.2006.05372.x. PMID16911518. S2CID25021929.